HIA
BMY.RT

Harbor Investment Advisory’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Harbor Investment Advisory’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,500
Closed -$2K – 1339
2020
Q4 		$2K Sell
2,500
-1,190
-32% -$2.54K ﹤0.01% 1132
2020
Q3 		$8K Sell
3,690
-730
-17% -$2.08K ﹤0.01% 889
2020
Q2 		$16K Buy
+4,420
New +$15.9K ﹤0.01% 699

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Harbor Investment Advisory's BMY.RT Position: Q1 2021 in Review

Harbor Investment Advisory sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 2,500 shares — an estimated $2K sold.

Harbor Investment Advisory first reported a position in BMY.RT in Q2 2020 and held it in 3 quarters. The position peaked at $16K in Q2 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Harbor Investment Advisory reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Harbor Investment Advisory sold 2,500 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $2K.
  • Harbor Investment Advisory first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q2 2020 and held it in 3 quarters.
  • Harbor Investment Advisory's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $16K in Q2 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Harbor Investment Advisory's 13F filing for Q1 2021, filed 16 Apr 2021.